Form 4: Co-Diagnostics President's Routine Stock Transactions

Sentiment:

Insider Transaction Report


Co-Diagnostics President Richard David Abbott reported the vesting of 56,667 restricted stock units and the sale of 17,200 shares to cover tax obligations.

Summary

  • Richard David Abbott, President of Co-Diagnostics, Inc. (CODX), reported transactions involving the company's common stock.
  • On November 23, 2025, 56,667 shares of common stock were acquired at a price of $0.00, resulting from the vesting of Restricted Stock Units (RSUs).
  • These vested shares are part of two RSU awards: 120,000 units awarded on April 26, 2024, and 220,000 units awarded on August 13, 2025, both under the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan.
  • The vesting occurs in 6 equal installments every 6 months, commencing on November 23, 2024, for the first award, and November 23, 2025, for the second award.
  • Concurrently, 17,200 shares of common stock were disposed of at a price of $0.35 per share.
  • This disposition represents a mandatory 'sell to cover' transaction to satisfy tax withholding obligations related to the RSU vesting, not a discretionary trade by Mr. Abbott.
  • Following these transactions, Mr. Abbott's direct beneficial ownership of common stock is 66,202 shares, and he holds 293,771 derivative Restricted Stock Units.

Sentiment

Score: 5

Explanation: The filing reports routine, pre-scheduled insider transactions related to executive compensation and mandatory tax withholding, indicating a neutral sentiment.

Positives

  • The vesting of 56,667 Restricted Stock Units represents a scheduled compensation event for the President, indicating continued executive incentive alignment.

Negatives

  • The sale of 17,200 shares, while mandatory for tax purposes, reduces the President's direct beneficial ownership of common stock.

Stakeholder Impact

  • Shareholders: The transactions are routine executive compensation events and mandatory tax-related sales, which are generally expected and have minimal direct impact on the company's operational or strategic direction.
  • Employees: Reflects standard executive compensation practices under the company's long-term incentive plan.

Next Steps

  • Future installments of the 120,000 Restricted Stock Units will continue to vest every 6 months from November 23, 2024.
  • Future installments of the 220,000 Restricted Stock Units will continue to vest every 6 months from November 23, 2025.

Key Dates

DateDescription
2015Co-Diagnostics, Inc. 2015 Long Term Incentive Plan established, under which RSUs were awarded.
04/26/2024Award date for 120,000 Restricted Stock Units to the Reporting Person.
11/23/2024Commencement date for the vesting of the 120,000 Restricted Stock Units (first of 6 equal installments every 6 months).
08/13/2025Award date for 220,000 Restricted Stock Units to the Reporting Person.
11/23/2025Date of earliest transaction, including RSU vesting and sell-to-cover; also the commencement date for the vesting of the 220,000 Restricted Stock Units (first of 6 equal installments every 6 months).

Keywords

CODX, Insider Transaction, Form 4, Restricted Stock Units, RSU Vesting, Executive Compensation, Sell to Cover, Stock Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.